Patrick Flume to Lung Diseases
This is a "connection" page, showing publications Patrick Flume has written about Lung Diseases.
Connection Strength
3.089
-
Inhaled nitric oxide for adults with pulmonary non-tuberculous mycobacterial infection. Respir Med. 2023 01; 206:107069.
Score: 0.709
-
Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease. Chest. 2021 12; 160(6):2042-2050.
Score: 0.645
-
Chest Computed Tomography Features of Nontuberculous Mycobacterial Pulmonary Disease Versus Asymptomatic Colonization: A Cross-sectional Cohort Study. J Thorac Imaging. 2022 May 01; 37(3):140-145.
Score: 0.645
-
Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2011 Nov; 17(6):442-7.
Score: 0.329
-
The clinical approach to lung disease in patients with cystic fibrosis. Semin Respir Crit Care Med. 2009 Oct; 30(5):505-13.
Score: 0.284
-
Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial. Ann Am Thorac Soc. 2021 07; 18(7):1147-1157.
Score: 0.161
-
Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure. Chest. 2021 09; 160(3):831-842.
Score: 0.158
-
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018 12 15; 198(12):1559-1569.
Score: 0.135
-
Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Med. 1994 Oct 13; 331(15):981-7.
Score: 0.025